SCHEMBL1701693

SCHEMBL1701693

O=C(O)NC(=S)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
EPHX1 P07099 3/20 0.47
POLB P06746 1/20 0.47
CES1 P23141 3/20 0.46
ALOX15 P16050 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CES2 O00748 2/20 0.46
DAO P14920 1/20 0.46
TSHR P16473 1/20 0.46
NAPRT Q6XQN6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062971 0.85 POLB (0.54) ALDH1A1HPGDNPC1RAB9AEPHX1
SCHEMBL3077377 0.84 ALDH1A1 (0.67) ALDH1A1NPC1RAB9AEPHX1ALOX15
SCHEMBL11470090 0.84 ALDH1A1 (0.50) ALDH1A1HPGDNPC1RAB9AEPHX1
SCHEMBL3077991 0.82 ALDH1A1 (0.59) ALDH1A1HPGDEPHX1POLBCES1
SCHEMBL5365743 0.82 EPHX1 (0.55) ALDH1A1HPGDNPC1RAB9AEPHX1
SCHEMBL28158557 0.80 CES2 (0.48) ALDH1A1NPC1RAB9AEPHX1POLB
SCHEMBL4054997 0.79 NPC1 (0.47) ALDH1A1HPGDNPC1RAB9APOLB
SCHEMBL6501458 0.79 ALDH1A1 (0.55) ALDH1A1HPGDNPC1RAB9AEPHX1
SCHEMBL11922851 0.77 SMN1; SMN2 (0.54) ALDH1A1NPC1RAB9AEPHX1POLB
SCHEMBL1816064 0.77 GAA (0.51) ALDH1A1HPGDNPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106074591-B RNA interference in ocular symptoms 菲奥医药公司 2020-01-14 CN disclosed
EP-2566334-B1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2018-04-18 EP disclosed
EP-2566335-B1 CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES PROLYNX LLC (US) 2016-06-29 EP disclosed
US-8946405-B2 Controlled release from solid supports PROLYNX LLC (US) 2015-02-03 US disclosed
US-8754190-B2 Controlled release from macromolecular conjugates PROLYNX LLC (US) 2014-06-17 US disclosed
US-8703907-B2 Controlled drug release from dendrimers PROLYNX LLC (US) 2014-04-22 US disclosed
US-20130123487-A1 CONTROLLED RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2013-05-16 US disclosed
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2013-05-16 US disclosed
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES PROLYNX LLC 2013-05-09 US disclosed
EP-2571496-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS Prolynx Llc (US) 2013-03-27 EP disclosed
EP-2566335-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES Prolynx Llc (US) 2013-03-13 EP disclosed
EP-2566334-A1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS Prolynx Llc (US) 2013-03-13 EP disclosed
WO-2011140376-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2011-11-10 WO disclosed
WO-2011140393-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES PROLYNX LLC (US) 2011-11-10 WO disclosed
WO-2011140392-A1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2011-11-10 WO disclosed
WO-2008070014-A2 BIARYL KETONE-SUBSTITUTED PIPERIDINES NEUROGEN CORPORATION (US) 2008-06-12 WO disclosed
US-4138264-A Silver halide emulsion containing two equivalent type coupler for use in photography KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1979-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123487-A1 CONTROLLED RELEASE FROM SOLID SUPPORTS SLC43A1, ABCB1, NAPA ALDH1A1 3598/4885HPGD 2136/4885NPC1 608/4885
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS SLC43A1, SLC47A1, SLC47A2 ALDH1A1 2780/4885HPGD 2129/4885NPC1 2257/4885
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES ABCB1, ABCB11, GUSB ALDH1A1 1951/4885HPGD 2123/4885NPC1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.